Fulgent Genetics, Inc. (NASDAQ:FLGT) Shares Sold by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund cut its holdings in Fulgent Genetics, Inc. (NASDAQ:FLGT) by 12.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,609 shares of the company’s stock after selling 1,324 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in Fulgent Genetics were worth $177,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the business. GAMMA Investing LLC lifted its stake in Fulgent Genetics by 45.5% in the 4th quarter. GAMMA Investing LLC now owns 2,133 shares of the company’s stock valued at $39,000 after buying an additional 667 shares in the last quarter. Exchange Traded Concepts LLC lifted its position in shares of Fulgent Genetics by 5.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 35,324 shares of the company’s stock valued at $652,000 after acquiring an additional 1,689 shares in the last quarter. Centiva Capital LP boosted its stake in shares of Fulgent Genetics by 16.5% during the third quarter. Centiva Capital LP now owns 12,538 shares of the company’s stock valued at $272,000 after acquiring an additional 1,774 shares during the last quarter. Point72 DIFC Ltd acquired a new stake in shares of Fulgent Genetics during the third quarter valued at $46,000. Finally, TCW Group Inc. increased its position in Fulgent Genetics by 2.7% during the 4th quarter. TCW Group Inc. now owns 123,400 shares of the company’s stock worth $2,279,000 after purchasing an additional 3,300 shares in the last quarter. 48.06% of the stock is owned by hedge funds and other institutional investors.

Fulgent Genetics Stock Up 1.6 %

FLGT stock opened at $15.52 on Wednesday. The stock has a market capitalization of $474.71 million, a price-to-earnings ratio of -2.81 and a beta of 1.39. The stock’s fifty day simple moving average is $17.19 and its 200-day simple moving average is $19.32. Fulgent Genetics, Inc. has a 52-week low of $14.57 and a 52-week high of $25.11.

Analysts Set New Price Targets

A number of research firms have issued reports on FLGT. StockNews.com lowered shares of Fulgent Genetics from a “hold” rating to a “sell” rating in a report on Wednesday, November 27th. Piper Sandler reduced their price objective on shares of Fulgent Genetics from $22.00 to $16.00 and set a “neutral” rating on the stock in a research note on Tuesday.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.